Prof. Dr. ir. Geert RAES
Academic Staff - Myeloid Cell Immunology Team
Academic Staff - Dendritic Cell Biology & Cancer Immunotherapy Team
Biography
Geert Raes is staff scientist and valorization manager at the VIB Myeloid Cell Immunology lab and the Vrije Universiteit Brussel Cellular and Molecular Immunology lab. In addition to being trained as an immunologist, with a focus on tumour immunology and in vivo applications of nanobodies, he has experience in compiling, coordinating, reporting on and valorization of scientific projects with a focus on collaborative projects and interaction with industry. He is co-founder of the VUB spin-off companies Precirix and Abscint.
PUBLICATIONS
CONCLUSION: This study describes the development of a more specific human CD8^(+) T-cell-targeting immunotracer, allowing follow-up of immunotherapy responses by non-invasive imaging of human CD8^(+) T-cell dynamics.
Blockade of the immune checkpoint axis consisting of programmed death-1 (PD-1) and its ligand PD-L1 alleviates the functional inhibition of tumor-infiltrating lymphoid cells yet weakly induces their expansion. Exogenous cytokines could further expand lymphoid cells and thus synergize with αPD-L1 therapy. However, systemic delivery of most cytokines causes severe toxicity due to unspecific expansion of immune cells in the periphery. Here, we modelled local delivery of cytokines and αPD-L1...
INTRODUCTION: T cell Ig and ITIM domain receptor (TIGIT) is a next-generation immune checkpoint predominantly expressed on activated T cells and NK cells, exhibiting an unfavorable prognostic association with various malignancies. Despite the emergence of multiple TIGIT-blocking agents entering clinical trials, only a fraction of patients responded positively to anti-TIGIT therapy. Consequently, an urgent demand arises for noninvasive techniques to quantify and monitor TIGIT expression,...
INTRODUCTION: Monoclonal antibodies have revolutionized personalized medicine for cancer in recent decades. Despite their broad application in oncology, their large size and complexity may interfere with successful tumor targeting for certain applications of cancer diagnosis and therapy. Nanobodies have unique structural and pharmacological features compared to monoclonal antibodies and have successfully been used as complementary anti-cancer diagnostic and/or therapeutic tools.
Location
Room E8.08
Vrije Universiteit Brussel
Pleinlaan 2
1050 Brussels
Belgium